Healthy
Conditions
Brief summary
This study is to compare PK, PD, safety, tolerability, and immunogenicity profiles of SB16, EU sourced Prolia, and US sourced Prolia in healthy male subjects.
Interventions
DRUGDenosumab
60 mg, single-dose
Sponsors
Samsung Bioepis Co., Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
MALE
Age
28 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
1. Healthy male, aged 28-55 years (inclusive) on the day of signing the informed consent. 2. Have a body weight between 60.0-90.0 kg (inclusive) and a BMI between 20.0-29.9 kg/m2 (inclusive). 3. Have 12-lead ECG results without clinically significant abnormal findings confirmed by the Investigator. 4. Have vital sign results without clinically significant abnormal findings confirmed by the Investigator. 5. Have physical examination results without clinically significant abnormal findings confirmed by the Investigator. 6. Male subjects who have not had surgical sterilisation must be willing to abstain from sexual intercourse or willing to use a condom in addition to having their female partner use another form of contraception, such as an intra-uterine device, oral contraceptive, injectable progesterone, sub-dermal implant, or tubal ligation unless their partners are infertile (confirmed with written verifications) during the treatment period. 7. Willing and able to comply with scheduled visits, treatment plan, clinical laboratory tests, and other study procedures including lifestyle considerations. 8. Able to provide written informed consent, which must be obtained prior to any study related procedures being performed. 9. Have competence in speaking, writing, and comprehending the local language(s) where the study is conducted.
Exclusion criteria
1. Have a history and/or current presence of clinically significant atopic allergy, hypersensitivity, or allergic reactions (either spontaneous or following drug administration), also including known or suspected clinically relevant drug hypersensitivity to denosumab or to any of the excipients. 2. Have a history of and/or current clinically significant gastrointestinal, renal, hepatic, cardiovascular, haematological, pulmonary, neurologic, metabolic, psychiatric disorder, drug or alcohol abuse, or allergic disease excluding mild asymptomatic seasonal allergies. 3. Have a history of bone disease or any medical condition that can affect bone metabolism (including osteoporosis, osteogenesis imperfecta, osteomalacia, hyperparathyroidism, hyperthyroidism, hypothyroidism, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Paget's disease of the bone, and malabsorption syndrome). 4. Have a history of malignancy (including lymphoma, leukaemia, and skin cancer). 5. Have ONJ or risk factors for ONJ such as invasive dental procedures or active periodontal disease within 180 days prior to Randomisation. 6. Have bone fractures within 180 days prior to Randomisation. 7. Have a history of serious infection (associated with hospitalisation and/or which required intravenous antibiotics) within 180 days prior to Randomisation. 8. Have a clinically significant active infection (bacterial, viral, or fungal) including skin infections within 28 days prior to Randomisation. 9. Have any systemic or local infection, a known risk for developing sepsis. 10. Have known intolerance to calcium or vitamin D supplements. 11. Have previously been exposed to denosumab (Prolia®/Xgeva®) and its biosimilar. 12. Have previously been exposed to a monoclonal antibody or fusion protein within 270 days (other than denosumab) prior to Randomisation and/or there is confirmed evidence or clinical suspicion of immunogenicity from previous exposure to a monoclonal antibody or fusion protein. 13. Have previously been exposed to an immunosuppressive agent or biological agent (any other than a monoclonal antibody or fusion protein) within 120 days prior to Randomisation. 14. Have received live vaccines(s) within 30 days prior to Randomisation or who will require live vaccine(s) during the study period. 15. Have a personal or family history of prolonged QT interval syndrome or Torsade de Pointes, or family history of sudden death. 16. Have any of the following abnormal laboratory test results: 1. Albumin-adjusted serum calcium levels below the LLN or above the ULN. 2. Serum creatinine levels above 1.5 × ULN. 3. Any other laboratory abnormalities assessed as clinically significant by the Investigator. 17. Have a positive test result for HBsAg, HCV antibody, or HIV 1or 2. 18. Have a history of immunodeficiency. 19. Have had surgery within 90 days prior to Randomisation, and/or plan to have an operation (including invasive dental procedure) during the study period. 20. Have a history and/or current presence of an illness (including, but not limited to respiratory symptoms \[e.g., difficulty breathing or persistent cough\] or low-grade fever) within 14 days prior to Randomisation that is classified as clinically significant by the Investigator. 21. Have smoked more than 10 cigarettes, 2 cigars, or 2 pipes per day within 90 days prior to Screening. 22. Have regular consumption of alcoholic beverages that exceeds 14 units per week. 23. Have a positive urinary drug screening result or alcohol breath test result at Screening or Day -1. 24. Have taken any prescription medicine or over-the-counter medicines (except paracetamol) that might have an effect on the objectives of the study in the opinion of the Investigator, within 30 days or 10 half-lives of the medication (whichever period is longer) prior to Randomisation. This includes medications such as, but not limited to: Bisphosphonates, parathyroid hormone, hormone replacement therapy, selective estrogen receptor modulators, calcitonin, calcitriol, glucocorticoids, fluoride, strontium, or anabolic steroids. 25. Have donated \> 100 mL blood or plasma within 28 days prior to Randomisation. 26. Have participated in another study with an investigational drug within 60 days prior to Randomisation or are currently participating in or intending to participate in another clinical study of an investigational drug before completion of all scheduled evaluation in this clinical study. 27. Subjects who, in the opinion of the Investigator, are not likely to complete the study for whatever reason. 28. Subject who is the Investigator or any sub-Investigator, research assistant, pharmacist, study coordinator, other staff, or relative thereof directly involved in the conduct of the clinical study. 29. Vulnerable subjects
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| AUCinf | Day 1 to Day 197 | Area under the concentration-time curve from time zero to infinity |
| AUClast | Day 1 to Day 197 | Area under the concentration-time curve from time zero to the last quantifiable concentration |
| Cmax | Day 1 to Day 197 | Maximum serum concentration |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| t1/2 | Day 1 to Day 197 | Terminal half-life |
| CL/F | Day 1 to Day 197 | Apparent clearance |
| %AUCextrap | Day 1 to Day 197 | Percentage of AUCinf due to extrapolation from Tlast to infinity |
| AUEC for CTX percent inhibition | Day 1 to Day 197 | Area under the effect curve from time zero to Day 197 for serum CTX percent inhibition |
| Tmax | Day 1 to Day 197 | Time to reach Cmax |
| Incidence of SAEs | Day 1 to Day 197 | Experience at least 1 SAE |
| Incidence of ADAs | Day 1 to Day 197 | Incidence of ADAs to denosumab |
| Incidence of NAbs | Day 1 to Day 197 | Incidence of NAbs to denosumab |
| Incidence of TEAEs | Day 1 to Day 197 | Experience at least 1 TEAE |
| Vz/F | Day 1 to Day 197 | Apparent volume of distribution during the terminal phase |
| λz | Day 1 to Day 197 | Terminal rate constant |
Countries
France, United States
Outcome results
None listed